[ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage].
Dirk
D
Einecke
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007279:Injections, Subcutaneous; D007388:Internal Medicine; D007902:Length of Stay; D008134:Long-Term Care; D010351:Patient Discharge; D011183:Postoperative Complications / Q000517:prevention & control; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban